By
AmyT on
January 3, 2011
Happy New Year, everyone! I’ve been mostly off-line this past week, attempting to enjoy the “break” while cleaning and sorting out our fresh-from-construction home. But even in that daze, I couldn’t help noticing all the fuss about MannKind’s Afrezza, which was supposed to be ruled upon by the FDA on Dec. 29.
The FDA has requested an additional four weeks to make a decision on this new inhalable insulin, after having postponed the decision by…
Read more »
Hearsay is that Al Mann, CEO of MannKind Corp., is one of those people who’s either brilliant, crazy, or a combination thereof. Probably the latter. And I guess you’d have to be to keep pushing ahead on developing a powdered inhalable insulin product in the wake of Pfizer’s colossal flop Exubera.
I interviewed Al Mann last November (when their product Afrezza was still spelled with an ‘s’). I thought his claims about this new mealtime…
Read more »
The research poster is a clever invention. It basically allows researchers to pack all the details of a study they’ve conducted — abstract, methodology, graphs and charts, overview of results — on a 30″ x 40″ piece of cardboard to show it off at scientific events, so that colleagues can walk by and absorb their work in 10 minutes or less. Over 1,600 posters like this were presented this year at the American Diabetes Association…
Read more »
